Novo Nordisk: EU approves Sylvan deal in China

(CercleFinance.com) - The European Commission has cleared the acquisition of joint control of Sylvan International Biotechnology, of China, by Novo Nordisk Foundation, of Denmark, and KKR, of the US.


The transaction mainly concerns the market for the development and production of edible mushroom mycelium.

The Commission concluded that the notified transaction would not raise competition concerns, given that the joint venture has negligible activities in the European Economic Area and that the combined market position of the companies resulting from the proposed transaction is limited.


Copyright (c) 2024 CercleFinance.com. All rights reserved.